-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Aquinnah announced today that it has entered into an R&D agreement with Roche to advance the development of brain-penetrating oral small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases
Stress granules are one way the body repairs itself after damage
Aquinnah's scientific team examined more than 250,000 compounds and found a variety of compounds that can clear stress granules, some of which can clear stress granules that contain the TDP-43 protein
Under the agreement, Aquinnah and Roche will collaborate on research activities until the selection of a lead drug candidate, after which Roche will be responsible for further research, development and global commercialization
References:
[1] AQUINNAH PHARMACEUTICALS ANNOUNCES COLLABORATION WITH ROCHE TO ADVANCE NEW THERAPIES FOR ALS AND OTHER NEURODEGENERATIVE DISEASES.